FDA Commissioner Scott Gottlieb resigns

FDA Commissioner Scott Gottlieb, MD, is resigning. Gottlieb has manned the agency since May 2017 and will leave his position in about a month.

A number of Trump appointees, particularly White House staffers, have left their positions prematurely. Compared to the administration’s stance on deregulation, Gottlieb has been “adept in issuing new rules,” the Wall Street Journal stated. The agency has taken a harder stance on supplements and is looking into the marketing practices of e-cigarettes.

“All of us at HHS are proud of the remarkable work Commissioner Gottlieb has done at the FDA,” HHS Secretary Alex Azar said in a statement March 5. “He has been an exemplary public health leader, aggressive advocate for American patients and passionate promoter of innovation. I will personally miss working with Scott on the important goals we share, and I know that is true for so many other members of the HHS family.”

Under Gottlieb’s lead, the agency has also focused on streamlining the approval of new, innovative medical devices and drugs that aim to improve healthcare outcomes and lower costs.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.